Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Filippo Crea

doi:10.1093/eurheartj/ehab277

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Filippo Crea

Research output: Contribution to journal › Article

Abstract

N/A

Original language	English
Pages (from-to)	2973-2985
Number of pages	13
Journal	European Heart Journal
Volume	42
DOIs	https://doi.org/10.1093/eurheartj/ehab277
Publication status	Published - 2021

Keywords

Clopidogrel
Humans
Percutaneous Coronary Intervention
Prasugrel Hydrochloride
Purinergic P2Y Receptor Antagonists
Ticagrelor

Access to Document

10.1093/eurheartj/ehab277

Cite this

@article{20e7f3f34dd64c668787d9e7f63b11f4,

title = "Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy",

abstract = "N/A",

keywords = "Clopidogrel, Humans, Percutaneous Coronary Intervention, Prasugrel Hydrochloride, Purinergic P2Y Receptor Antagonists, Ticagrelor, Clopidogrel, Humans, Percutaneous Coronary Intervention, Prasugrel Hydrochloride, Purinergic P2Y Receptor Antagonists, Ticagrelor",

author = "Filippo Crea",

year = "2021",

doi = "10.1093/eurheartj/ehab277",

language = "English",

volume = "42",

pages = "2973--2985",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

AU - Crea, Filippo

PY - 2021

Y1 - 2021

N2 - N/A

AB - N/A

KW - Clopidogrel

KW - Humans

KW - Percutaneous Coronary Intervention

KW - Prasugrel Hydrochloride

KW - Purinergic P2Y Receptor Antagonists

KW - Ticagrelor

KW - Clopidogrel

KW - Humans

KW - Percutaneous Coronary Intervention

KW - Prasugrel Hydrochloride

KW - Purinergic P2Y Receptor Antagonists

KW - Ticagrelor

UR - http://hdl.handle.net/10807/204471

U2 - 10.1093/eurheartj/ehab277

DO - 10.1093/eurheartj/ehab277

M3 - Article

SN - 0195-668X

VL - 42

SP - 2973

EP - 2985

JO - European Heart Journal

JF - European Heart Journal

ER -

Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this